Showing 2861-2870 of 4108 results for "".
- US FDA Approves Saphnelo for Lupushttps://practicaldermatology.com/news/us-fda-approves-saphnelo-for-lupus/2460876/The U.S. Food and Drug Administration (FDA) approved Saphnelo (anifrolumab-fnia) as a treatment for adults with systemic lupus erythematosus (SLE) who are receiving standard therapy. Developed by AstraZeneca, Saphnelo is a monoclonal antibody administered by intravenous (IV)
- Sasakawa Leprosy (Hansen's Disease) Launches New "Don't Forget Leprosy" Initiativehttps://practicaldermatology.com/news/sasakawa-leprosy-hansens-disease-new-initiative-dont-forget-leprosy/2460872/Sasakawa Leprosy (Hansen's Disease) Initiative is launching a campaign called "Don't Forget Leprosy" urging that activities against the disease are not sidelined amid the ongoing coronavirus pandemic. Beginning with a webinar on Aug. 4, 2021, the approximately 10-
- Survey: Cleansing Habits of Americans Are Not Up to Dermatologist Standardshttps://practicaldermatology.com/news/survey-cleansing-habits-of-americans-are-not-up-to-dermatologist-standards/2460871/Fully 91 percent of consumers agree that cleansing is important, only 23 percent say that a dermatologist would be pleased with their facial cleansing habits, according to a new survey conducted by CeraVe of 2,000 U.S. adults aged 18-40. This is why this CeraVe is helping
- Allergan Aesthetics Continues Partnership with Girls Inc.https://practicaldermatology.com/news/allergan-aesthetics-continues-partnership-with-girls-inc/2460869/Allergan Aesthetics is starting its third consecutive year of partnership with Girls Inc. and debuting Empowering Confidence Workshops, a nationwide mentoring initiative. Based on a 2020 Girls Inc. report, many girls have a hard time picturing themselves in science, technology, eng
- PASI-HD: Modification to PsO Severity Scale Aims at Mild-to-Moderate Diseasehttps://practicaldermatology.com/news/pasi-hd-modification-to-pso-severity-scale-aims-at-mild-to-moderate-disease/2460867/A new modification to the Psoriasis Area and Severity Index (PASI) aims to address limitations of the scale when used to assess mild-to-moderate disease. PASI-high discrimination (PASI-HD), designed to be used in clinical trials among patients for whom the areas of affected body surface are less
- Hoth Therapeutics, Inc.’s BioLexa in AD: So Far, So Safehttps://practicaldermatology.com/news/hoth-therapeutics-incs-biolexa-in-ad-so-far-so-safe/2460853/Hoth Therapeutics, Inc.’s BioLexa was well tolerated with no serious adverse events and no drug-related treatment-emergent adverse events observed, according to the safety results in Cohort 1 of its first in human clinical trial of the BioLexa platform to treat atopic dermatitis.
- New AKN Classification System May Improve Treatmenthttps://practicaldermatology.com/news/new-akn-classification-system-may-improve-treatment/2460852/A new classification system aims to improve the way that Acne Keloidalis Nuchae or AKN is treated. AKN can begin as tiny bumps on the back of the head, typically following a close haircut. However, due to a patient's genetic predisposition, these lesions become unremitt
- European Commission Approves Libtayo as First Immunotherapy for Patients with Advanced BCChttps://practicaldermatology.com/news/european-commission-approves-libtayo-as-first-immunotherapy-for-patients-with-advanced-bcc/2460851/The PD-1 inhibitor Libtayo® (cemiplimab, Regeneron/Sanofi) is approved by the European Commission to treat adults with locally advanced or metastatic basal cell carcinoma (BCC) who have progressed on or are intolerant to a hedgehog pathway inhibitor (HHI). Libtayo is now approved for thr
- New Research Explores Nanotechnology as a Vehicle for Delivering Cannabinoids in Dermatologyhttps://practicaldermatology.com/news/new-research-explores-nanotechnology-as-a-vehicle-for-delivering-cannabinoids-in-dermatology/2460849/Nanotechnology delivery systems may be an innovative and effective approach to delivering cannabinoids for skin care, according to a team from the Department of Dermatology at the George Washington University School of Medicine and Health Sciences in Washington, DC. Research fellow Naga
- Study: Skin Reactions After COVID-19 Vaccines Are Rarehttps://practicaldermatology.com/news/study-skin-reactions-after-covid-19-vaccines-are-rare/2460848/Skin problems such as itchiness, rashes, hives and swelling can occur in some individuals after receiving a COVID-19 vaccine, but new research suggests that these reactions are rare, and that even when they do occur with an initial COVID-19 vaccination, they seldom recur after receiving a second